CANADIAN CANCER TRIALS GROUP – GI DISEASE SITE COMMITTEE

ESOPHAGO-GASTRIC
DISEASE ORIENTED GROUP

AGENDA
OPEN SESSION
VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 29th, 2017
TIME: 08:00 – 09:00
CHAIR: DR. REBECCA WONG

08:00  WELCOME AND INTRODUCTION  DR. R. WONG

08:00  ACTIVE/RECENTLY CLOSED TRIALS FOR UPDATE

**GA.1 (TOP GEAR):** A RANDOMIZED PHASE III TRIAL OF PREOPERATIVE CHEMORADIOThERAPY VERSUS PREOPERATIVE CHEMoThERAPY FOR RESECTABLE GASTRIC CANCER  
**DR. R. WONG**

**GA.1 (TOPGEAR):** OPTIMIZING ACCRUAL – LESSONS LEARNED FROM CANADA’S TOP ACCRUING SITE  
**DR. M. TEHFE (DR. M. LIBERMAN)**

**GA.3 (INTEGRATE II) –** A RANDOMIZED PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF REGORAFENIB IN REFRACTORY ADVANCED OESOPHAGO-GASTRIC CANCER (AOGC)  
**DR. T. ALCINDOR**

**IND 214:** A PHASE I/II STUDY OF MG1 MARABA/MAGE-A3 (MG1MA3), WITH AND WITHOUT ADENOVIRUS VACCINE, WITH TRANSGENIC MAGE-A3 INSERTION (ADMA3) IN PATIENTS WITH INCURABLE ADVANCED/METASTATIC MAGE-A3-EXPRESSING SOLID TUMOURS  
**DR. D. JONKER**

08:30  NEW CONCEPTS IN DEVELOPMENT

A RANDOMIZED PHASE II STUDY OF CISPLATIN + GEMCITABINE VS STANDARD OF CARE IN PATIENTS WITH EBV+ GASTRIC CANCER.  
**DR. R. WONG (DR. ERIC CHEN)**

**THE NEEDS TRIAL:** NEOADJUVANT CHEMORADIOThERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA VERSUS DEFINITIVE CHEMORADIOThERAPY WITH SALVAGE SURGERY AS NEEDED  
**DR. R. WONG**

PHASE II/III TRIAL COMPARING TWO CHEMOTHERAPY REGIMENS IN DEFINITIVE CHEMORADIOThERAPY FOLLOWED BY PET/BIOPSY DIRECTED BRACHYThERAPY FOR PATIENTS WITH CANCER OF ESOPHAGUS WHO ARE NOT ELIGIBLE FOR SURGERY  
**DR. A. MAHMUD**

08:55  INTERGROUP TASK FORCE UPDATE  DR. R. WONG

09:00  CLOSING REMARKS